{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:21:48Z","timestamp":1763547708858,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study assessed the short- and long-term outcomes of intravitreal (IVT) faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) refractory to aflibercept. The main aim was to investigate whether faricimab might enable longer treatment intervals versus aflibercept through improved fluid control, evaluated through use of an artificial intelligence-based quantification tool to evaluate retinal fluid dynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational cohort study involved patients with refractory nAMD who received at least three consecutive IVT aflibercept 2.0\u00a0mg injections before switching to IVT faricimab (with a four-month loading phase followed by a treat-and-extend regimen) due to persistent or recurrent disease despite 4\u20138-week treatment intervals. Functional and anatomical outcome measures were recorded, and fluid volume dynamics were quantified, at baseline, monthly to Month 4, and at Months 6, 9, and 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-four eyes from 60 patients were included, with a mean\u2009\u00b1\u2009standard deviation duration of prior aflibercept therapy of 24\u2009\u00b1\u200917 months. Fifty-two eyes completed 12-month follow-up. At Month 12, mean best-corrected visual acuity showed no significant change from baseline (+\u20090.01 Early Treatment of Diabetic Retinopathy Study letters,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.64). Significant reductions in mean central retinal thickness (\u2212\u200980.8\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001) and maximal pigment epithelium detachment (PED) height (\u2212\u200928.2\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), were observed at Month 4 and maintained to Month 12. Mean fluid volumes (intraretinal fluid [IRF], subretinal fluid [SRF]), and PED decreased significantly at Month 4 (\u2212\u200926.3 nL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007; \u221241.5 nL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001; and \u2212\u2009175.4 nL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001, respectively). At Month 12, reductions in IRF and PED volumes were sustained. The maximal fluid-free interval increased from 4.4 weeks, prior to switching to faricimab, to 6.5 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) after switching, while mean last treatment interval improved from 5.0\u2009\u00b1\u20091.4 weeks at baseline to 7.3\u2009\u00b1\u20092.6 weeks at month 12 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Faricimab may offer a valuable alternative for patients with refractory nAMD. The use of four loading injections administered monthly, followed by a treat-and-extend regimen can result in maintenance of visual acuity and improve anatomical parameters and retinal fluid activity, allowing for longer treatment intervals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00751-9","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:18:26Z","timestamp":1763547506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3686-120X","authenticated-orcid":false,"given":"Mickael","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-7176","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3697-9121","authenticated-orcid":false,"given":"Yannic Pannatier","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Chiara","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-5126","authenticated-orcid":false,"given":"Daniela Gallo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadou Path\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3400","authenticated-orcid":false,"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"12","key":"751_CR1","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.3390\/biomedicines11123221","volume":"11","author":"L Finocchio","year":"2023","unstructured":"Finocchio L, Zeppieri M, Gabai A, Toneatto G, Spadea L, Salati C. Recent developments in gene therapy for neovascular age-related macular degeneration: a review. Biomedicines. 2023;11(12):3221.","journal-title":"Biomedicines"},{"issue":"6","key":"751_CR2","first-page":"514","volume":"6","author":"PG Schlottmann","year":"2017","unstructured":"Schlottmann PG, Alezzandrini AA, Zas M, Rodriguez FJ, Luna JD, Wu L. New treatment modalities for neovascular age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017;6(6):514\u20139.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"14","key":"751_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"14","key":"751_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"751_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"12","key":"751_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"10326","key":"751_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"10432","key":"751_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"10432","key":"751_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/DDDT.S368963","volume":"16","author":"AA Nair","year":"2022","unstructured":"Nair AA, Finn AP, Sternberg P. Jr. Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy. Drug Des Devel Ther. 2022;16:3395\u2013400.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"751_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825\u201330.","journal-title":"Drugs"},{"key":"751_CR12","unstructured":"Genentech FDA. Approves genentech\u2019s vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss. 2022. updated 28.01.2022. Available from: https:\/\/www.gene.com\/media\/press-releases\/14943\/2022-01-28\/fda-approves-genentechs-vabysmo-the-firs."},{"issue":"11","key":"751_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"751_CR14","doi-asserted-by":"publisher","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","volume":"2","author":"G Thurston","year":"2012","unstructured":"Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin\u2013Tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2(9):a006550.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"751_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","volume":"28","author":"RM Hussain","year":"2019","unstructured":"Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2\/angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28(10):861\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"15","key":"751_CR16","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valentin-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37(15):3282\u20139.","journal-title":"Eye (Lond)"},{"issue":"1","key":"751_CR17","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13(1):8747.","journal-title":"Sci Rep"},{"issue":"17","key":"751_CR18","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"4","key":"751_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8(4):360\u20136.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"751_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina. 2024;8(1):10\u20137.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"751_CR21","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","volume":"12","author":"S Inoda","year":"2023","unstructured":"Inoda S, Takahashi H, Takahashi R, et al. Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history. Ophthalmol Ther. 2023;12(5):2703\u201312.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"751_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1151\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"751_CR24","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13(1):21128.","journal-title":"Sci Rep"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"issue":"15","key":"751_CR26","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12(15):5145.","journal-title":"J Clin Med"},{"issue":"6","key":"751_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from Aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537\u201344.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"751_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular Age-Related macular degeneration data: consensus on neovascular Age-Related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336.","journal-title":"Ophthalmology"},{"issue":"2","key":"751_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjo-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration National database. Br J Ophthalmol. 2024;108(2):253\u201362.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"751_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.10.4.17","volume":"10","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, et al. Automated quantification of pathological fluids in neovascular age-related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol. 2021;10(4):17.","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"751_CR31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjo-2024-325615","volume":"109","author":"R Martin-Pinardel","year":"2025","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, et al. Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care National age-related macular degeneration database. Br J Ophthalmol. 2025;109(10):1161\u201370.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"751_CR32","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s40123-025-01239-3","volume":"14","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, et al. Early outcome analysis of intravitreal Aflibercept 8\u00a0mg treatment in Na\u00efve patients with neovascular Age-Related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025;14(11):2819\u201329.","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"751_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares V, Schmidt-Erfurth UM, Leingang O, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol. 2024;108(7):971\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"751_CR34","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41433-024-03532-0","volume":"39","author":"AA Aziz","year":"2025","unstructured":"Aziz AA, Khanani AM, Khan H, et al. Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study. Eye (Lond). 2025;39(6):1099\u2013106.","journal-title":"Eye (Lond)"},{"issue":"5","key":"751_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/aos.17458","volume":"103","author":"M Michl","year":"2025","unstructured":"Michl M, Gerendas BS, Gruber A, et al. Comparison of AI-based retinal fluid monitoring in neovascular age-related macular degeneration with manual assessment by different eye care professionals under optimized conditions. Acta Ophthalmol. 2025;103(5):552\u201360.","journal-title":"Acta Ophthalmol"},{"key":"751_CR36","doi-asserted-by":"crossref","unstructured":"Cheung GCM, Lim JI, Priglinger S, et al. Anatomic outcomes with faricimab vs. aflibercept in the head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular AMD. Ophthalmology. 2024.","DOI":"10.1016\/j.ophtha.2024.11.023"},{"issue":"12","key":"751_CR37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/s41433-020-0803-6","volume":"34","author":"KX Cheong","year":"2020","unstructured":"Cheong KX, Grewal DS, Teo KYC, Gan ATL, Jaffe GJ, Cheung GCM. The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye (Lond). 2020;34(12):2257\u201363.","journal-title":"Eye (Lond)"},{"issue":"3","key":"751_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3928\/23258160-20180221-03","volume":"49","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Banaee T, Silva FQ, Singh RP. Switching Anti-Vascular endothelial growth factors in refractory neovascular Age-Related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49(3):166\u201370.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00751-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:18:28Z","timestamp":1763547508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00751-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00751-9","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the local ethics committee for data collection and analysis and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written consent was obtained for all patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}